Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR-Reference-Cited by-同舟云学术

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

Published:2010-09-02 Issue:10 Volume:24 Page:1719-1724
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ross D M,Branford S,Seymour J F,Schwarer A P,Arthur C,Bartley P A,Slader C,Field C,Dang P,Filshie R J,Mills A K,Grigg A P,Melo J V,Hughes T P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010185.pdf

Reference25 articles.

1. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080–7085.

2. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

3. Ross DM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. Blood 2008; 112: 402–403, Abstract no. 1102.

4. Mahon FX, Rea D, Guilhot F, Legros L, Guilhot J, Aton E et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial. J Clin Oncol 2009; 27, Abstract no. 7084.

5. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.

Cited by 237 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia;Scientific Reports;2023-10-24

3. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I;Current Molecular Pharmacology;2023-10-02

4. Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing;PLOS Global Public Health;2023-09-12

5. The Recurrent Atypical e8a2 <i>BCR::ABL1</i> Transcript with Insertion of an Inverted 55 Base Pair <i>ABL1</i> Intron 1b Sequence: A Detailed Molecular Analysis;Acta Haematologica;2023-05-19